Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.

Publication Type:

Journal Article


Clinical cancer research : an official journal of the American Association for Cancer Research, Volume 15, Issue 14, p.4759-68 (2009)


2009, Animals, Antigens, CD40, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Center-Authored Paper, Clinical Research Division, Clone Cells, Cytotoxicity, Immunologic, Female, Flow Cytometry Core Facility, Graft vs Host Disease, hematopoietic stem cell transplantation, Hematopoietic Stem Cells, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Leukocytes, Mononuclear, Male, MICE, Middle Aged, Minor Histocompatibility Antigens, Myeloablative Agonists, NIH 3T3 Cells, Shared Resources, T-Lymphocytes, Transplantation, Homologous, Treatment Outcome, Vidarabine


Allogeneic nonmyeloablative hematopoietic stem cell transplant (NM-HSCT) can result in durable remission of chronic lymphocytic leukemia (CLL). It is thought that the efficacy of NM-HSCT is mediated by recognition of tumor cells by T cells in the donor stem cell graft. We evaluated the development of CTLs specific for CLL after NM-HSCT to determine if their presence correlated with antitumor efficacy.